SKYSCRAPER-01NCT04294810
A Study of Tiragolumab in Combination With Atezolizumab Compared With Placebo in Combination With Atezolizumab in Patients With Previously Untreated Locally Advanced Unresectable or Metastatic PD-L1-Selected Non-Small Cell Lung Cancer
Free. We email you which fields changed when ClinicalTrials.gov updates this record.
Record History
All 48 versions: 47 with changes below, 1 re-verified with no change. See every version on ClinicalTrials.gov ↗
Notable Results posted: Nov 9, 2026 Show 5 more changesShow less
- Eligibility criteria expanded, about 18 words
- Primary endpoints: 4 to 8
- Study sites: 134 to 132
- Secondary endpoints: 7 to 28
- Publications: 1 to 2
- Minor Trial status: Active, Not Recruiting to Completed
- Study sites: 132 to 134
- Primary and study completion dates changed from estimate of Jan 31, 2026 to Dec 30, 2025
- Minor Study sites: 140 to 132
- Primary and study completion dates: Dec 31, 2025 to Jan 31, 2026
- Minor Study sites: 141 to 140v45
- Notable Primary and study completion dates pushed to Dec 31, 2025
- Study sites revised (141)
Show 41 earlier versionsHide 41 earlier versions
- Minor Primary completion date changed from estimate of Dec 1, 2025 to Sep 24, 2024v43
- Notable Primary and study completion dates: Feb 21, 2025 to Dec 1, 2025
- Study sites: 154 to 141
- Minor Study sites revised (154)v41
- Minor Site details revised at 2 of 154 sitesv40
- Minor Study sites revised (154)v39
- Minor Study sites revised (154)v38
- Minor Study sites: 153 to 154v36
- Minor Trial status: Recruiting to Active, Not Recruiting
- Enrollment target: estimated 660 to confirmed 620
- Study sites: 180 to 153
- Minor Site details revised at 2 of 180 sitesv34
- Minor Site details revised at 4 of 180 sitesv33
- Minor Site details revised at 5 of 180 sitesv32
- Minor Site details revised at 4 of 180 sitesv31
- Minor Study sites: 179 to 180v30
- Minor Study sites: 177 to 179v29
- Minor Study sites: 176 to 177v28
- Minor Site details revised at 12 of 176 sitesv27
- Minor Site details revised at 1 of 176 sitesv26
- Minor Study sites revised (176)v25
- Minor Study sites revised (176)v24
Notable Primary completion date: Aug 25, 2023 to Feb 21, 2025v23 Show 4 more changesShow less
- Primary endpoints: 2 to 4
- Enrollment target: 635 to 660
- Secondary endpoints: 14 to 7
- Site details revised at 5 of 176 sites
- Notable Primary completion date: Aug 25, 2022 to Aug 25, 2023
- Study sites: 154 to 176
Notable Eligibility criteria expanded, about 20 wordsv21 Show 4 more changesShow less
- Primary endpoints revised (2)
- Enrollment target: 560 to 635
- Study sites: 153 to 154
- Secondary endpoints: 16 to 14
- Minor Study sites: 173 to 153v20
- Minor Site details revised at 20 of 173 sitesv19
- Minor Study sites revised (173)v18
- Minor Site details revised at 10 of 173 sitesv17
- Minor Site details revised at 13 of 173 sitesv16
- Minor Study sites: 172 to 173v15
- Minor Study sites revised (172)v14
- Minor Site details revised at 15 of 172 sitesv13
- Minor Study sites revised (172)v12
- Minor Study sites revised (172)v11
Notable Primary endpoints revised (2)v10 Show 4 more changesShow less
- Eligibility criteria shortened, about 4 words
- Enrollment target: 500 to 560
- Secondary endpoints: 14 to 16
- Site details revised at 17 of 172 sites
- Minor Study sites: 169 to 172v9
- Minor Study sites: 154 to 169v8
- Minor Study sites: 152 to 154v7
- Minor Study sites: 151 to 152v6
Notable Eligibility criteria shortened, about 6 wordsv5 Show 4 more changesShow less
- Primary endpoints revised (2)
- Interventions: Atezolizumab (Drug), Matching Placebo (Other), Tiragolumab (Drug) to Atezolizumab (Drug), Matching Placebo (Drug), Tiragolumab (Drug)
- Secondary endpoints revised (14)
- Study sites revised (151)
- Minor Site details revised at 20 of 151 sitesv4
- Minor Site details revised at 4 of 151 sitesv3
- Notable Trial status: Not Yet Recruiting to Recruiting
- Study sites: 129 to 151
- Start date changed from estimate of Feb 28, 2020 to Mar 4, 2020
- Study First Submitted
- Notable: the plan changed
- Minor: routine updates
Endpoints
Primary
Secondary (28)
Show 23 moreShow less
Arms and interventions
Participants will receive atezolizumab followed by tiragolumab every 3 weeks (Q3W) on Day 1 of each 21-day cycle until disease progression, loss of clinical benefit or unacceptable toxicity.
Participants will receive atezolizumab followed by placebo Q3W on Day 1 of each 21-day cycle until disease progression, loss of clinical benefit or unacceptable toxicity.
Drugs: Atezolizumab, Tiragolumab, Matching Placebo
Sites
132 sites in 23 countries
China 18, Japan 12, South Korea 12, Italy 9, Taiwan 8, United States 8, Germany 7, Russia 6, Spain 6, Turkey (Türkiye) 6, Greece 4, Netherlands 4, Peru 4, Thailand 4, Australia 3, Austria 3, Hungary 3, Mexico 3, Poland 3, Switzerland 3, Brazil 2, Serbia 2, Ukraine 2